REFERENCES
2. Senore C, Lansdorp-Vogelaar I, de Jonge L, Rabeneck L. Rationale for organized colorectal cancer screening programs. Best Pract Res Clin Gastroenterol 2023;66:101850.
3. Ogunwobi OO, Mahmood F, Akingboye A. Biomarkers in colorectal cancer: current research and future prospects. Int J Mol Sci 2020;21:5311.
4. Saeed O, Lopez-Beltran A, Fisher KW, et al. RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications. J Clin Pathol 2019;72:135-9.
5. Bylsma LC, Gillezeau C, Garawin TA, et al. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: a systematic review and meta-analysis. Cancer Med 2020;9:1044-57.
6. Gawiński C, Michalski W, Mróz A, Wyrwicz L. Correlation between lymphocyte-to-monocyte ratio (LMR), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and tumor-infiltrating lymphocytes (TILs) in left-sided colorectal cancer patients. Biology 2022;11:385.
7. Sur D, Advani S, Braithwaite D. MicroRNA panels as diagnostic biomarkers for colorectal cancer: a systematic review and meta-analysis. Front Med 2022;9:915226.
8. Li X, Zhang S, Zeng J, et al. Heterogeneous expression of mismatch repair proteins and interpretation of immunohistochemical results in colorectal cancer and endometrial cancer. Pathol Res Pract 2023;248:154647.
9. Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008;10:293-300.
10. Adeleke S, Haslam A, Choy A, et al. Microsatellite instability testing in colorectal patients with lynch syndrome: lessons learned from a case report and how to avoid such pitfalls. Per Med 2022;19:277-86.
11. Wools A, Dapper EA, de Leeuw JR. Colorectal cancer screening participation: a systematic review. Eur J Public Health 2016;26:158-68.
12. Mancini S, Ravaioli A, Falcini F, et al. Strategies for delivery of faecal occult blood test kits and participation to colorectal cancer screening in the Emilia-Romagna region of Italy. Eur J Cancer Care 2018;27:e12631.
13. Decreto del Presidente del Consiglio dei Ministri 12 Gennaio 2017. Definizione e aggiornamento dei livelli essenziali di assistenza, di cui all'articolo 1, comma 7, del decreto legislativo 30 dicembre 1992, n. 502. (17A02015) (GU Serie Generale n.65 del 18-03-2017 - Suppl. Ordinario n. 15). Available from: https://www.gazzettaufficiale.it/eli/id/2017/03/18/17A02015/sg [Last accessed on 20 Feb 2024].
14. EpiCentro-Istituto Superiore di Sanità. Sorveglianza PASSI. Screening colorettale. Indicatori - PASSI 2021-2022. Available from: https://www.epicentro.iss.it/passi/dati/ScreeningColorettale [Last accessed on 20 Feb 2024].
15. Masseria C. Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment. Eur J Health Econ 2010;10 Suppl 1:S41-9.
16. Bucchi L, Mancini S, Baldacchini F, et al. Emilia-Romagna Region Workgroup for Colorectal Screening Evaluation. How a faecal immunochemical test screening programme changes annual colorectal cancer incidence rates: an Italian intention-to-screen study. Br J Cancer 2022;127:541-8.
17. Karsa L, Patnick J, Segnan N; European Commission, Directorate-General for Health and Consumers, Executive Agency for Health and Consumers, World Health Organization. European guidelines for quality assurance in colorectal cancer screening and diagnosis. In: Karsa L, Patnick J, Segnan N, editors. Organisation. Luxembourg: Publications Office of the European Union; 2010. p. 50. Avaliable from: https://op.europa.eu/en/publication-detail/-/publication/e1ef52d8-8786-4ac4-9f91-4da2261ee535 [Last accessed on 23 Feb 2024].
18. Lindsey L, Husband A, Nazar H, Todd A. Promoting the early detection of cancer: a systematic review of community pharmacy-based education and screening interventions. Cancer Epidemiol 2015;39:673-81.
19. Santolaya M, Aldea M, Grau J, et al. Evaluating the appropriateness of a community pharmacy model for a colorectal cancer screening program in Catalonia (Spain). J Oncol Pharm Pract 2017;23:26-32.
20. Thomson K, Hillier-Brown F, Walton N, Bilaj M, Bambra C, Todd A. The effects of community pharmacy-delivered public health interventions on population health and health inequalities: a review of reviews. Prev Med 2019;124:98-109.
21. Della Valle PG, Deandrea S, Battisti F, et al. The community pharmacy model for colorectal cancer screening: policy insights from a national programme. Res Soc Adm Pharm 2023;19:1595-601.
22. Chiereghin A, Squillace L, Pizzi L, Bazzani C, Roti L, Mezzetti F. Applying the healthcare failure mode and effects analysis approach to improve the quality of an organised colorectal cancer screening programme. J Med Screen 2023.
23. Urionagüena A, Piquer-Martinez C, Gastelurrutia MÁ, et al. Community pharmacy and primary health care - types of integration and their applicability: a narrative review. Res Soc Adm Pharm 2023;19:414-31.
24. Hirst Y, Skrobanski H, Kerrison RS, et al. Text-message reminders in colorectal cancer screening (TRICCS): a randomised controlled trial. Br J Cancer 2017;116:1408-14.
25. EpiCentro-Istituto Superiore di Sanità. Gli screening oncologici e l’impatto della pandemia: i dati dalla sorveglianza PASSI. Available from: https://www.epicentro.iss.it/passi/focus/screening-oncologici-impatto-pandemia-dati-passi-2020 [Last accessed on 20 Feb 2024].
26. Vives N, Milà N, Binefa G, et al. Role of community pharmacies in a population-based colorectal cancer screening program. Prev Med 2021;145:106420.
27. Burón A, Grau J, Andreu M, et al. Colorectal cancer early screening program of Barcelona, Spain: indicators of the first round of a program with participation of community pharmacies. Med Clin 2015;145:141-6.
28. Prentice A, Marshall S, Vance M, et al. Colorectal cancer screening and the role of community pharmacy. Pharm J 2019;302:7921.
29. National Institute for Health and Care Excellence. Community pharmacies: promoting health and wellbeing. NICE guideline [NG102]. 2018. Available from: https://www.nice.org.uk/guidance/ng102 [Last accessed on 20 Feb 2024].
